Exxon Mobil’s XTO Energy Explores Sale of Eagle Ford Shale Assets in South Texas 
Samsung Set to Begin HBM4 Production for Nvidia and AMD 
Shell Plc Downgraded by RBC as Market Headwinds Pressure Valuation 
Airbus CEO Warns Staff to Prepare for Rising Geopolitical Risks Amid Trade Tensions 
Elon Musk Shares Bold Vision for AI, Robots, and Space at Davos 
Baker Hughes Reports 11% Rise in Q4 Adjusted Profit Driven by LNG Demand 
Toyota Recalls 162,000 Tundra Vehicles in U.S. Over Multimedia Display Issue 
Trump Lawsuit Against JPMorgan Signals Rising Tensions Between Wall Street and the White House 
NTSB Opens Investigation Into Waymo Robotaxis After School Bus Safety Violations in Texas 
SEC Drops Gemini Enforcement Case After Full Repayment to Earn Investors 
Trump Administration Takes Stake in USA Rare Earth to Boost U.S. Critical Minerals Supply 
Microsoft Restores Microsoft 365 Services After Widespread Outage 
Embraer Targets Growth as Regional Jet Demand Surges Post-Pandemic 
ByteDance Finalizes Majority U.S.-Owned TikTok Joint Venture to Avert American Ban 
Ericsson Plans SEK 25 Billion Shareholder Returns as Margins Improve Despite Flat Network Market 
Intel Stock Slides Despite Earnings Beat as Weak Q1 Outlook Raises Concerns 
PLAINSBORO, N.J., May 12, 2017 -- Integra LifeSciences Holdings Corporation (Nasdaq:IART), a leading global medical technology company, today announced the launch of SurgiMend MP, its latest offering in tissue-building solutions for complex abdominal hernia repair. SurgiMend MP is a strong, 2mm thick acellular collagen matrix featuring a highly macroporous design that facilitates fluid drainage. The product offers physicians a biologic, yet cost-effective alternative to resorbable synthetic mesh to support healing, tissue building, and prolonged reinforcement in abdominal hernia repair.
|
|||||
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/24d233ad-f70b-4b5b-9880-c686e49bf26a
“The addition of SurgiMend MP to our portfolio of biologic soft tissue repair products for hernia repair, and plastic and reconstructive surgery, provides general, trauma, colorectal, and plastic and reconstructive surgeons with another innovative solution in their surgical tool set,” said Bob Davis, corporate vice president and president, Orthopedics and Tissue Technologies. “We believe SurgiMend MP will significantly strengthen our ability to limit uncertainty for surgeons looking to meet the challenging hernia repair needs of their patients with complex abdominal wall conditions.”
SurgiMend MP is intended for implantation to reinforce soft tissue where weakness exists and for surgical repair of damaged or ruptured soft tissue membranes. SurgiMend MP is specifically indicated for plastic and reconstructive surgery, muscle flap reinforcement, and hernia repair, including abdominal, inguinal, femoral, diaphragmatic, scrotal, umbilical, and incisional hernias. SurgiMend MP will be available in numerous sizes ranging from 10cm x 15cm up to 25cm x 40cm to meet the varying needs of surgeons and their patients.
About Integra
Integra LifeSciences is dedicated to limiting uncertainty for clinicians, so they can concentrate on providing the best patient care. Integra offers innovative solutions, including leading plastic and regenerative technologies, in specialty surgical solutions, and orthopedics and tissue technologies. For more information, please visit www.integralife.com.
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the products and services provided by Integra. Such forward looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of surgical professionals to use Integra products may affect the prospects for their use in surgical procedures. In addition, the economic, competitive, governmental, technological and other factors, identified under the heading "Risk Factors" included in Item IA of Integra's Annual Report on Form 10-K for the year ended December 31, 2016 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.
CONTACT: Integra LifeSciences Holdings Company Investors: Nora Brennan 609 936 2488 Michael Beaulieu 609 750 2827 [email protected] Media: Laurene Isip 609 750 7984 [email protected]
